Curated News
By: NewsRamp Editorial Staff
March 11, 2026

NeuroThera & Clearmind Patent Novel Therapy for Obesity & Liver Disease

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • NeuroThera Labs' patent for a MEAI-PEA combination therapy could offer a safer, more cost-effective alternative to GLP-1 agonists in the rapidly growing $226 billion weight loss market.
  • The therapy combines Clearmind's MEAI platform with NeuroThera's PEA to create a non-hallucinogenic neuroplastogen treatment targeting obesity and metabolic dysfunction-associated steatotic liver disease.
  • This novel therapy addresses two major global health challenges affecting over 890 million adults with obesity and 30% with liver disease, potentially improving lives worldwide.
  • A biotech collaboration has produced a patent for a non-hallucinogenic neuroplastogen that could revolutionize treatment for obesity and fatty liver disease through a unique MEAI-PEA combination.

Impact - Why it Matters

This development matters because it addresses two interconnected global health epidemics affecting billions: obesity and metabolic liver disease. Current treatments like GLP-1 agonists, while effective for some, come with significant side effects, high costs, and accessibility challenges. This novel MEAI-PEA combination therapy promises a safer, non-hallucinogenic alternative that could be more cost-effective and tolerable for long-term use. Given that obesity and MASLD contribute to numerous other serious conditions including diabetes, cardiovascular disease, and liver failure, a breakthrough treatment could reduce healthcare burdens, improve quality of life for millions, and offer a sustainable solution in a market projected to exceed $200 billion. The collaboration between NeuroThera and Clearmind represents the kind of innovative partnership needed to tackle complex chronic diseases through combined therapeutic approaches rather than single-compound solutions.

Summary

NeuroThera Labs Inc., a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., has significantly advanced its collaboration with Clearmind Medicine Inc. through the publication of an international patent application for a novel combination therapy. This groundbreaking treatment targets two major global health crises: obesity, which affects over 890 million adults worldwide, and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease), impacting approximately 30% of the global adult population. The therapy combines Clearmind's 5-methoxy-2-aminoindane (MEAI) platform with NeuroThera's Palmitoylethanolamide (PEA), aiming to create a safe, non-hallucinogenic neuroplastogen that could revolutionize treatment options in these critical areas.

The core innovation lies in the potential of this MEAI-PEA combination to offer a safer, easier, and more cost-effective alternative to existing GLP-1 agonists, which currently dominate the obesity and MASLD treatment landscape. This development arrives at a pivotal moment, as the global weight loss drugs market is experiencing explosive growth—valued at approximately $37 billion in 2025 and forecasted to reach $226 billion by 2035. The companies are strategically positioning themselves to address the escalating demand for effective, tolerable, and safe treatments, leveraging Clearmind's extensive intellectual portfolio, which includes nineteen patent families and thirty-one granted patents, to build a robust foundation for this promising therapeutic approach.

This collaboration represents a significant step forward in the pharmaceutical industry's response to chronic health conditions that burden healthcare systems worldwide. By focusing on novel combinations rather than standalone compounds, NeuroThera and Clearmind are pioneering a path that could lead to more accessible and sustainable treatment options. For further information about Clearmind's innovative work, interested parties can visit their official website. The original news release provides comprehensive details on this development and can be viewed on www.newmediawire.com, offering deeper insights into the patent publication and the companies' strategic vision for addressing these pervasive health challenges through cutting-edge biotechnological innovation.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroThera & Clearmind Patent Novel Therapy for Obesity & Liver Disease

blockchain registration record for this content.